Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.82 |
| ▸ | NPC1 | O15118 | 4/20 | 0.82 |
| ▸ | BCHE | P06276 | 1/20 | 0.80 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | AR | P10275 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | TXN | P10599 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425175 | 0.90 | RAB9A (1.00) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL11475158 | 0.89 | BCHE (1.00) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL2948524 | 0.89 | RAB9A (0.91) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL9729274 | 0.87 | NPC1 (0.88) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL21639229 | 0.87 | NPC1 (0.88) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL11535096 | 0.87 | NPC1 (0.88) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL7998438 | 0.86 | BCHE (0.73) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL14304932 | 0.86 | BCHE (0.86) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL31175737 | 0.86 | BCHE (0.73) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 | |
| SCHEMBL6530086 | 0.84 | BCHE (0.83) | RAB9ANPC1BCHEEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-4211839-A | SILVER HALIDE AND ORGANIC SILVER SALT PREPARED IN AN IMINO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-08 | — | — | US | claimed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-20210317407-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-10-14 | — | — | US | disclosed |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2021-07-29 | — | — | US | disclosed |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2019-07-11 | — | — | US | disclosed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | ABEL-SANTOS ERNESTO (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016127102-A2 | INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS | ABEL-SANTOS ERNESTO (US) | 2016-08-11 | — | — | WO | disclosed |
| EP-2203459-B1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009035684-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-0594726-B1 | BENZIMIDAZOLE ANTHELMINTIC AGENTS | PFIZER LTD (GB) | 1997-01-29 | — | — | EP | disclosed |
| US-4216284-A | NONDIFFUSIBLE SILVER BLEACH INHIBITOR | FUJI PHOTO FILM CO., LTD. (JP) | 1980-08-05 | — | — | US | disclosed |
| US-4211839-A | SILVER HALIDE AND ORGANIC SILVER SALT PREPARED IN AN IMINO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | RAB9A 2633/4885NPC1 682/4885BCHE 3951/4885 |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | RAB9A 4497/4885NPC1 1750/4885BCHE 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.